blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2749282

EP2749282 - Method of treating atrial fibrillation [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.06.2018
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  07.07.2017
FormerGrant of patent is intended
Status updated on  19.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
GILEAD SCIENCES, INC.
333 Lakeside Drive Foster City
California 94404 / US
[2014/27]
Inventor(s)01 / Antzelevitch, Charles
101 Sylvan Way
New Hartford, NY New York 13413 / US
02 / Belardinelli, Luiz
205 Manzanita Ave.
Palo Alto, CA California 94304 / US
03 / Burashnikov, Alexander
59 Imperial Dr.
New Hartford, NY New York 13413 / US
04 / Shryock, John
2313 Vines Ct.
East Palo Alto, CA California 94303 / US
05 / Zeng, Dewan
871 Sycamore Dr.
Palo Alto, CA California 94303 / US
 [2014/27]
Representative(s)Wallace, Sheila Jane, et al
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[N/P]
Former [2014/27]Wallace, Sheila Jane, et al
Marks & Clerk LLP
90 Long Acre
London WC2E 9RA / GB
Application number, filing date14161300.020.12.2010
[2014/27]
Priority number, dateUS20090288739P21.12.2009         Original published format: US 288739 P
[2014/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2749282
Date:02.07.2014
Language:EN
[2014/27]
Type: B1 Patent specification 
No.:EP2749282
Date:09.08.2017
Language:EN
[2017/32]
Search report(s)(Supplementary) European search report - dispatched on:EP08.05.2014
ClassificationIPC:A61K31/343, A61K31/495, A61P9/06
[2014/27]
CPC:
A61K31/495 (EP,KR,US); A61K31/343 (EP,KR,US); A61K45/06 (EP,US);
A61P43/00 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/06 (EP); A61P9/10 (EP) (-)
C-Set:
A61K31/343, A61K2300/00 (EP,US);
A61K31/495, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/32]
Former [2014/27]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA19.12.2014
ME19.12.2014
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON VORHOFFLIMMERN[2016/47]
English:Method of treating atrial fibrillation[2014/27]
French:METHODE DE TRAITEMENT DE LA FIBRILLATION AURICULAIRE[2016/47]
Former [2014/27]Verfahren zur Behandlung von Vorhofflimmern
Former [2014/27]Méthode de traitement de la fibrillation auriculaire
Examination procedure19.12.2014Amendment by applicant (claims and/or description)
19.12.2014Examination requested  [2015/05]
09.03.2016Despatch of a communication from the examining division (Time limit: M04)
19.07.2016Reply to a communication from the examining division
20.02.2017Communication of intention to grant the patent
30.06.2017Fee for grant paid
30.06.2017Fee for publishing/printing paid
30.06.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10798436.1  / EP2515900
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20100798436) is  03.05.2013
Opposition(s)11.05.2018No opposition filed within time limit [2018/29]
Fees paidRenewal fee
24.03.2014Renewal fee patent year 03
24.03.2014Renewal fee patent year 04
29.12.2014Renewal fee patent year 05
28.12.2015Renewal fee patent year 06
27.12.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.12.2010
AL09.08.2017
CY09.08.2017
DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
MC09.08.2017
MK09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
LU20.12.2017
MT20.12.2017
[2020/34]
Former [2019/52]HU20.12.2010
CY09.08.2017
DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
MC09.08.2017
MK09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
LU20.12.2017
MT20.12.2017
Former [2019/46]HU20.12.2010
CY09.08.2017
DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
MC09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
LU20.12.2017
MT20.12.2017
Former [2019/31]HU20.12.2010
DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
MC09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
LU20.12.2017
MT20.12.2017
Former [2019/30]DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
MC09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
LU20.12.2017
MT20.12.2017
Former [2018/43]DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
LU20.12.2017
MT20.12.2017
Former [2018/26]DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
RO09.08.2017
RS09.08.2017
SM09.08.2017
BG09.11.2017
IS09.12.2017
Former [2018/23]DK09.08.2017
EE09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
RO09.08.2017
RS09.08.2017
BG09.11.2017
IS09.12.2017
Former [2018/21]DK09.08.2017
FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
RS09.08.2017
BG09.11.2017
IS09.12.2017
Former [2018/12]FI09.08.2017
HR09.08.2017
LT09.08.2017
LV09.08.2017
RS09.08.2017
BG09.11.2017
IS09.12.2017
Former [2018/11]FI09.08.2017
HR09.08.2017
LT09.08.2017
RS09.08.2017
BG09.11.2017
IS09.12.2017
Former [2018/08]FI09.08.2017
LT09.08.2017
Former [2018/07]LT09.08.2017
Documents cited:Search[A]WO2009150535  (SANOFI AVENTIS [FR], et al) [A] 1-15 * page 2, lines 15-17; claim 1 *;
 [AD]  - FOR THE ERATO STUDY INVESTIGATORS ET AL, "Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 156, no. 3, doi:10.1016/J.AHJ.2008.06.010, ISSN 0002-8703, (200809), pages 527.E1 - 527.E9, (20080827), XP025470440 [AD] 1-15 * abstract * * page 527.e2, column 2, paragraph 2 * * page 527.e7, column 2, paragraph 4 - page 527.e8, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.ahj.2008.06.010
 [A]  - KUMAR KAPIL ET AL, "New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future.", CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, (200910), vol. 11, no. 5, ISSN 1534-3189, pages 373 - 380, XP002631255 [A] 1-15 * abstract * * page 374, paragraph 6 - page 375, paragraph 1 * * page 378, paragraphs 2-3 *
 [AD]  - ANTZELEVITCH C ET AL, "Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation", JOURNAL OF ELECTROCARDIOLOGY, ELSEVIER SCIENCE, vol. 42, no. 6, doi:10.1016/J.JELECTROCARD.2009.07.007, ISSN 0022-0736, (200911), pages 543 - 548, (20090820), XP026702881 [AD] 1-15 * abstract * * page 546, column 1, paragraph 6 - column 2, paragraph 3 * * page 547, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.jelectrocard.2009.07.007
 [AD]  - SCIRICA BENJAMIN M ET AL, "Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of Arrhythmias in patients with Non-ST-Segment-Elevation acute coronary syndrome - Thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Randomized controlled trial", CIRCULATION, (200710), vol. 116, no. 15, ISSN 0009-7322, pages 1647 - 1652, XP002631256 [AD] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1161/circulationaha.107.724880
 [A]  - GRAMLEY FELIX ET AL, "Recent advances in the pharmacological treatment of cardiac arrythmias.", DRUGS OF TODAY, BARCELONA, SPAIN, (200911), vol. 45, no. 11, ISSN 1699-3993, pages 807 - 824, XP002631257 [A] 1-15 * page 817, column 2, lines 34-35 *
 [AD]  - BURASHNIKOV ALEXANDER ET AL, "Author Manuscript:Atrial-selective sodium channel block for the treatment of atrial fibrillation.", NIH Public Access, (200906), pages 1 - 25, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756337/pdf/nihms125373.pdf, (20110405), XP002631258 [AD] 1-15 * the whole document * * Published in final edited form as: Expert Opin Emerg Drugs. 2009 June, 14(2). 233-249 *
 [AD]  - SICOURI S ET AL, "Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations", HEART RHYTHM, ELSEVIER, US, vol. 5, no. 7, doi:10.1016/J.HRTHM.2008.03.018, ISSN 1547-5271, (200807), pages 1019 - 1026, (20080321), XP022819454 [AD] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.hrthm.2008.03.018
 [AD]  - HOHNLOSER STEFAN H ET AL, "Effect of dronedarone on cardiovascular events in atrial fibrillation", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20090212), vol. 360, no. 7, doi:10.1056/NEJMOA0803778, ISSN 1533-4406, pages 668 - 678, XP002604030 [AD] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1056/NEJMoa0803778
by applicantUS3845770
 US4326525
 US4567264
 US4902514
 US5223510
 US5472707
 US5506229
 US5616345
 US6503911
 US6852724
 US6939865
 US7022343
 US2006177502
 US7323493
    - FUSTER ET AL., CIRCULATION, (2006), vol. 114, no. 7, pages E257 - 354
    - ROY ET AL., NENGL JMED, (2008), vol. 358, no. 25, pages 2667 - 2677
    - Remington's Pharmaceutical Sciences, 17th Edition,, (1985), page 1418
    - SONG ET AL., AM JPHYSIOL, (2008), vol. 294, pages H2031 - 2039
    - SICOURI ET AL., HEART RHYTHM, (2008), vol. 5, pages 1019 - 1026
    - ANTZELEVITCH ET AL., CIRCULATION, (2004), vol. 110, pages 904 - 910
    - BURASHNIKOV ET AL., CIRCULATION, (2007), vol. 116, pages 1449 - 1457
    - KURRIAR ET AL., J CARDIOVASC ELECTROPHYSIOL, (2009), vol. 20, pages 796 - 802
    - KUMAR ET AL., J CARDIOVASC ELECTROPHYSIOL, (2009), vol. 20, pages 796 - 802
    - SONG ET AL., AM J PHYSIOL, (2008), vol. 294, pages H2031 - 2039
    - LI ET AL., CIRCULATION, (2000), vol. 101, pages 2631 - 2638
    - VERHEULE, CIRCULATION, (2003), vol. 107, pages 2615 - 2622
    - KISTLER ET AL., EUR HEART J, (2006), vol. 27, pages 3045 - 3056
    - KIRCHHOF ET AL., J CARDIOVASC. ELECTROPHYSIOL, (2003), vol. 14, pages 1027 - 1033
    - ANTZELE,4TCH ET AL., CIRCULATION, (2004), vol. 110, pages 904 - 910
    - VAN WAGONER D., J CARDIOVASC PHARM, (2008), vol. 52, pages 306 - 313
    - GO AS; HYLEK EM; PHILLIPS KA; CHANG Y; HENAULT LE; SELBY JV; SINGER DE, "Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study", JAMA, (2001), vol. 285, pages 2370 - 2375
    - ZIMETBAUM PJ, "Dronedarone for atrial fibrillation-an odyssey", NENGL JMED, (2009), vol. 360, doi:doi:10.1056/NEJMp0902248, pages 1811 - 1813, XP055016654

DOI:   http://dx.doi.org/10.1056/NEJMp0902248
    - PICCINI JP; HASSELBLAD V; PETERSON ED; WASHAM JB; CALIFF RM; KONG DF, "Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation", JAM COLL CARDIOL., (2009), vol. 54, doi:doi:10.1016/j.jacc.2009.04.085, pages 1089 - 1095, XP026583351

DOI:   http://dx.doi.org/10.1016/j.jacc.2009.04.085
    - TOUBOUL P; BRUGADA J; CAPUCCI A; CRIJNS HJ; EDVARDSSON N; HOHNLOSER SH, "Dronedarone for prevention of atrial fibrillation: a dose-ranging study", EUR HEART J., (2003), vol. 24, doi:doi:10.1016/S0195-668X(03)00321-X, pages 1481 - 1487, XP007905686

DOI:   http://dx.doi.org/10.1016/S0195-668X(03)00321-X
    - SINGH BN; CONNOLLY SJ; CRIJNS HJ; ROY D; KOWEY PR; CAPUCCI A; RADZIK D; ALIOT EM; HOHNLOSER SH, "Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter", N ENGL JMED., (2007), vol. 357, doi:doi:10.1056/NEJMoa054686, pages 987 - 999, XP007905685

DOI:   http://dx.doi.org/10.1056/NEJMoa054686
    - DAVY JM; HEROLD M; HOGLUND C; TIMMERMANS A; ALINGS A; RADZIK D; VAN KL., "Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the control of ventricular rate during atrial fibrillation (ERATO) study", AM HEART J., (2008), vol. 156, pages 527.E1 - 527.E9
    - KOBER L; TORP-PEDERSEN C; MCMURRAY JJ; GOTZSCHE 0; LEVY S; CRIJNS H; AMLIE J; CARLSEN J, "Increased mortality after dronedarone therapy for severe heart failure", N ENGL JMED., (2008), vol. 358, doi:doi:10.1056/NEJMoa0800456), pages 2678 - 2687, XP055016653

DOI:   http://dx.doi.org/10.1056/NEJMoa0800456)
    - HOHNLOSER SH; CRIJNS HJ; VAN EM; GAUDIN C; PAGE RL; TORP-PEDERSEN C; CONNOLLY SJ, "Effect of dronedarone on cardiovascular events in atrial fibrillation", NENGL JMED., (2009), vol. 360, doi:doi:10.1056/NEJMoa0803778, pages 668 - 678, XP002664648

DOI:   http://dx.doi.org/10.1056/NEJMoa0803778
    - BURASHNIKOV A; DI DIEGO JM; ZYGMUNT AC; BELARDINELLI L; ANTZELEVITCH C, "Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine", CIRCULATION, (2007), vol. 116, pages 1449 - 1457
    - BURASHNIKOV A; DI DIEGO JM; SICOURI S; FERREIRO M; CARLSSON L; ANTZELEVITCH C, "Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation", HEART RHYTHM., (2008), vol. 5, doi:doi:10.1016/j.hrthm.2008.09.015, pages 1735 - 1742, XP025781327

DOI:   http://dx.doi.org/10.1016/j.hrthm.2008.09.015
    - SICOURI S; GLASS A; BELARDINELLI L; ANTZELEVITCH C, "Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations", HEART RHYTHM, (2008), vol. 5, doi:doi:10.1016/j.hrthm.2008.03.018, pages 1019 - 1026, XP022819454

DOI:   http://dx.doi.org/10.1016/j.hrthm.2008.03.018
    - SICOURI S; BELARDINELLI L; CARLSSON L; ANTZELEVITCH C., "Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations", J CARDIOVASC ELECTROPHYSIOL., (2009), vol. 20, pages 803 - 810
    - KUMAR K; NEARING BD; CARVAS M; NASCIMENTO BC; ACAR M; BELARDINELLI L; VERRIER RL, "Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart", J CARDIOVASC ELECTROPHYSIOL., (2009), vol. 20, pages 796 - 802
    - ANTZELEVITCH C; BELARDINELLI L; ZYGMUNT AC; BURASHNIKOV A; DI DIEGO JM; FISH JM; CORDEIRO JM; THOMAS GP, "Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties", CIRCULATION, (2004), vol. 110, pages 904 - 910
    - BURASHNIKOV A; MANNAVA S; ANTZELEVITCH C, "Transmembrane action potential heterogeneity in the canine isolated arterially-perfused atrium: effect of Ikr and Ito/Ikur block", AM JPHYSIOL., (2004), vol. 286, pages H2393 - H2400
    - PATTERSON E; PO SS; SCHERLAG BJ; LAZZARA R, "Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation", HEART RHYTHM, (2005), vol. 2, doi:doi:10.1016/j.hrthm.2005.02.012, pages 624 - 631, XP004931677

DOI:   http://dx.doi.org/10.1016/j.hrthm.2005.02.012
    - PATTERSON E; LAZZARA R; SZABO B; LIU H; TANG D; LI YH; SCHERLAG BJ; PO SS, "Sodium-calcium exchange initiated by the Ca2+ transient: an arrhythmia trigger within pulmonary veins", JAM COLL CARDIOL., (2006), vol. 47, doi:doi:10.1016/j.jacc.2005.12.023, pages 1196 - 1206, XP029653114

DOI:   http://dx.doi.org/10.1016/j.jacc.2005.12.023
    - CHEN YJ; CHEN SA; CHANG MS; LIN CI, "Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation", CARDIOVASC RES., (2000), vol. 48, pages 265 - 273
    - CHEN YJ; CHEN SA, "Electrophysiology of pulmonary veins", J CARDIOVASC ELECTROPHYSIOL., (2006), vol. 17, pages 220 - 224
    - FUSTER V; RYDEN LE; CANNOM DS; CRIJNS HJ; CURTIS AB; ELLENBOGEN KA; HALPERIN JL; LE HEUZEY JY; KAY GN; LOWE JT, "ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit", JAM COLL CARDIOL., (2006), vol. 48, doi:doi:10.1016/j.jacc.2006.07.009, pages 854 - 906, XP029653177

DOI:   http://dx.doi.org/10.1016/j.jacc.2006.07.009
    - REIFFEL, J. A., "Rate versus rhythm control pharmacotherapy for atrial fibrillation: where are we in 2008?", JOURNAL>, (2008), vol. 1, pages 31 - 47
    - NACCARELLI GV; GONZALEZ MD, "Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future?", J CARDIOVASC PHARMACOL., (2008), vol. 52, pages 203 - 209
    - CAIN ME; CURTIS AB, "Rhythm control in atrial fibrillation--one setback after another", N ENGL J MED., (2008), vol. 358, pages 2725 - 2727
    - SAVELIEVA I; CAMM J, "Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches", EUROPACE, (2008), vol. 10, doi:doi:10.1093/europace/eun130, pages 647 - 665, XP008096587

DOI:   http://dx.doi.org/10.1093/europace/eun130
    - HAISSAGUERRE M; JAIS P; SHAH DC; TAKAHASHI A; HOCINI M; QUINIOU G; GARRIGUE S; LE MOUROUX A; LE METAYER P; CLEMENTY J., "Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins", NENGL JMED, (1998), vol. 339, pages 659 - 666
    - SHAH DC; HAISSAGUERRE M; JAIS P; CLEMENTY J, "High-resolution mapping of tachycardia originating from the superior vena cava: evidence of electrical heterogeneity, slow conduction, and possible circus movement reentry", J CARDIOVASC ELECTROPHYSIOL., (2002), vol. 13, pages 3 8 8 - 3 92
    - NATTEL S; SHIROSHITA-TAKESHITA A; BRUNDEL BJ; RIVARD L, "Mechanisms of atrial fibrillation: lessons from animal models", PROG CARDIOVASC DIS., (2005), vol. 48, doi:doi:10.1016/j.pcad.2005.06.002, pages 9 - 28, XP026039091

DOI:   http://dx.doi.org/10.1016/j.pcad.2005.06.002
    - ANTZELEVITCH C; BURASHNIKOV A, "Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation", J ELECTROCARDIOL., (2009), vol. 42, doi:doi:10.1016/j.jelectrocard.2009.07.007, pages 543 - 548, XP026702881

DOI:   http://dx.doi.org/10.1016/j.jelectrocard.2009.07.007
    - VARRO A; TAKACS J; NEMETH M; HALA 0; VIRAG L; LOST N; BALATI B; AGOSTON M; VERECKEI A; PASTOR G, "Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone", BR J PHARMACOL, (2001), vol. 133, pages 625 - 634
    - GAUTIER P; GUILLEMARE E; MARION A; BERTRAND JP; TOURNEUR Y; NISATO D, "Electrophysiologic characterization of dronedarone in guinea pig ventricular cells", J CARDIOVASC PHARMACOL., (2003), vol. 41, pages 191 - 202
    - SUN W; SARMA JS; SINGH BN, "Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone", CIRCULATION, (1999), vol. 100, pages 2276 - 2281
    - SUN W; SARMA JS; SINGH BN, "Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone", J CARDIOVASC PHARMACOL., (2002), vol. 39, pages 677 - 684
    - MORO S; FERREIRO M; CCLESTINO D; MEDEI E; ELIZARI MV; SICOURI S, "In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle", J CARDIOVASC PHARMACOL THER, (2007), vol. 12, pages 314 - 321
    - MANNING A; THISSE V; HODEIGE D; RICHARD J; HEYNDRICKX JP; CHATELAIN P, "SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs", J CARDIOVASC PHARMACOL., (1995), vol. 25, doi:doi:10.1097/00005344-199502000-00010, pages 252 - 261, XP001024497

DOI:   http://dx.doi.org/10.1097/00005344-199502000-00010
    - VERDUYN SC; VOS MA; LEUNISSEN HD; VAN OPSTAL JM; WELLENS HJ, "Evaluation of the acute clectrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias", J CARDIOVASC PHARMACOL., (1999), vol. 33, doi:doi:10.1097/00005344-199902000-00006, pages 212 - 222, XP001024499

DOI:   http://dx.doi.org/10.1097/00005344-199902000-00006
    - FINANCE 0; MANNING A; CHATELAIN P, "Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs", J CARDIOVASC PHARMACOL., (1995), vol. 26, pages 570 - 576
    - SINGH BN, "Amiodarone as paradigm for developing new drugs for atrial fibrillation", J CARDIOVASC PHARMACOL., (2008), vol. 52, pages 300 - 305
    - SCIRICA BM; MORROW DA; HOD H; MURPHY SA; BELARDINELLI L; HEDGEPETH CM; MOLHOEK P; VERHEUGT FW; GERSH BJ; MCCABE CH, "Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrom", CIRCULATION, (2007), vol. 116, doi:doi:10.1161/circulationaha.107.724880, pages 1647 - 1652, XP002631256

DOI:   http://dx.doi.org/10.1161/circulationaha.107.724880
    - MURDOCK DK; OVERTON N; KERSTEN M; KALIEBE J; DEVECCHI F, "The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation", INDIAN PACING ELECTROPHYSIOL J, (2008), vol. 8, pages 175 - 181
    - MURDOCK DK; KERSTEN M; KALIEBE J; LARRIAN G, "The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a reveiw of experience with implications for possible ''pill in the pocket'' approach to atrial fibrillation", INDIAN PACING ELECTROPHYSIOL J, (2009), vol. 9, pages 260 - 267
    - GOLDSCHLAGER N; EPSTEIN AE; NACCARELLI GV; OLSHANSKY B; SINGH B; COLLARD HR; MURPHY E, "A practical guide for clinicians who treat patients with amiodarone: 2007", HEART RHYTHM., (2007), vol. 4, doi:doi:10.1016/j.hrthm.2007.07.020, pages 1250 - 1259, XP022219201

DOI:   http://dx.doi.org/10.1016/j.hrthm.2007.07.020
    - BARDY GH; LEE KL; MARK DB; POOLE JE; PACKER DL; BOINEAU R; DOMANSKI M; TROUTMAN C; ANDERSON J; JOHNSON G, "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", N ENGL J MED, (2005), vol. 352, pages 225 - 237
    - CONNOLLY SJ; CRIJNS HJ; TORP-PEDERSEN C; VAN EM, GAUDIN C; PAGE RL; HOHNLOSER SH, "Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter", CIRCULATION, (2009), vol. 120, doi:doi:10.1161/CIRCULATIONAHA.109.875252, pages 1174 - 1180, XP002664647

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.109.875252
    - KOREN MJ; CRAGER MR; SWEENEY M, "Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE", JAM COLL CARDIOL., (2007), vol. 49, doi:doi:10.1016/j.jacc.2006.10.067, pages 1027 - 1034, XP029654713

DOI:   http://dx.doi.org/10.1016/j.jacc.2006.10.067
    - CHAITMAN BR, "Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions", CIRCULATION, (2006), vol. 113, pages 2462 - 2472
    - MALTSEV VA; SABBAH HN; UNDROVINAS AI, "Late sodium current is a novel target for amiodarone: studies in failing human myocardium", J MOL CELL CARDIOL., (2001), vol. 33, pages 923 - 932
    - ANTZELEVITCH C, "Electrical heterogeneity, cardiac arrhythmias, and the sodium channel", CIRC RES., (2000), vol. 87, pages 964 - 965
    - ANTZELEVITCH C; BELARDINELLI L; WU L; FRASER H; ZYGMUNT AC; BURASHNIKOV A; DI DIEGO JM; FISH JM; CORDEIRO JM; GOODROW RJ, "Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent", J CARDIOVASC PHARMACOL THERAPEUT, (2004), vol. 9, no. 1, pages S65 - S83
    - SHRYOCK JC; BELARDINELLI L, "Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium", BR J PHARMACOL., (2008), vol. 153, doi:doi:10.1038/SJ.BJP.0707522, pages 1128 - 1132, XP002581022

DOI:   http://dx.doi.org/10.1038/SJ.BJP.0707522
    - BURASHNIKOV A; ANTZELEVITCH C, "Atrial-selective sodium channel block for the treatment of atrial fibrillation", EXPERT OPIN EMERG DRUGS, (2009), vol. 14, pages 233 - 249, XP009140792
    - PAPPONE C; SANTINELLI V; MANGUSO F; VICEDOMINI G; GUGLIOTTA F; AUGELLO G; MAZZONE P; TORTORIELLO V; LANDONI G; ZANGRILLO A, "Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation", CIRCULATION, (2004), vol. 109, pages 327 - 334
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.